Influenza a (H1N1)V: EMEA Status Report

Influenza a (H1N1)V: EMEA Status Report

Influenza at the interface between humans and animals Influenza A (H1N1)v: EMEA Status Report John Purves, European Medicines Agency (EMEA) 30 October 2009 1 Overview of presentation z Preparedness activities (2003-2009) z Current activities (April to October 2009) z Current situation - Vaccines 2 Overview of presentation z PreparednessPreparedness activitiesactivities (2003(2003--2009)2009) z Current activities (April to October 2009) z Current situation - Vaccines 3 Highlights of pandemic preparedness activities since 2003 2004 2006/7 - 2 CHMP Guidelines - Assessor training on EMEA pandemic adopted introducing procedures & assessment issues 2009 concept of a core - CHMP recommendations on PV plan as part of - Registration of pandemic dossier (mock the RMP of pandemic vaccines MAAs Celvapan H5N1 up vaccine) - Registration of Focetria H5N1 MAA MAA 2003 2005/6 2007/8 -Extensive - EMEA publishes - Update of antiviral review by CHMP pandemic EMEA pandemic plan - EMEA Pandemic communications plan & preparatory work presentation to SANCO & ECDC at EMEA, with - EMEA Pandemic business continuity planning and industry, since exercise 2003 -Joint EMEA–NCA BCP pandemic workshop - Registration of Pandemrix H5N1 MAA 4 What is a Mock-Up Pandemic Vaccines? z Mock-up vaccine is a vaccine containing viral antigen(s) to which humans are immunologically naïve, e.g. H9N2 / H5N1. z Scientific data with a mock-up vaccine are relevant for the pandemic vaccine: » Manufacturing and quality data » Clinical experience in naïve population » Evaluation of novel concepts prior to a pandemic e.g. use of adjuvants with the objective of increasing available doses, establishment of dosing schedule 5 Mock up strategy Marketing Quality,Quality,Quality, safety,safety,safety, efficacyefficacyefficacy Authorisation CoreCoreCore dossierdossierdossier usingusingusing aaa strainstrainstrain e.g.e.g.e.g. H5N1H5N1H5N1 (MA) – Mock up (H5N1) SupplementarySupplementarySupplementary qualityqualityquality datadatadata Pandemic ononon thethethe newnewnew strainstrainstrain Vaccine MA (“quality(“quality(“quality variation”variation”variation” to to to thethethe MA)MA)MA) (H1N1) a)a) FollowFollow upup ClinicalClinical datadata b)b) RiskRisk ManagementManagement PlanPlan 6 Mock-Up Pandemic Vaccines Product name Adjuvanted/ non- MAH adjuvanted FOCETRIA Adjuvanted with MF59 Novartis Vaccines and Diagnostics S.r.l MAA approved on 2nd May 2007 PANDEMRIX Adjuvanted with AS03 GlaxoSmithKline Biologicals SA MAA approved on 20th May 2008 CELVAPAN Not Adjuvanted Baxter AG MAA approved on 4th March 2009 7 What has been done by the EMEA? z In order to get approval of pandemic vaccines as soon as possible after an outbreak of pandemic: » Strategy was to update the 3 mock-up MAs (based on H5N1 data), which had already been approved with data on new virus strain A (H1N1)v » 3 vaccines: Focetria (Novartis), Pandemrix (GSK Biologicals) and Celvapan (Baxter) z Follow-up of pandemic vaccines / antivirals once approved z Clear Communications on issues within remit of EMEA 8 Overview of presentation z Preparedness activities (2003-2009) z CurrentCurrent activitiesactivities (April(April toto OctoberOctober 2009)2009) z Current situation - Vaccines 9 Highlights of pandemic activities since April 2009 April 2009 29 September - Novel A(H1N1)v cases emerged in 6 October Mexico and USA- reported end April 2009 2009 2009 August 2009 -Pandemic - EC decision on -Start of variation received - EMEA began frequent discussions EC decision on pandemic with experts /manufacturers for Manufacturing of Focetria and variation H1N1 novel A(H1N1)v vaccines the vaccines Pandemrix for Celvapan 11 June 2009 September 2009 From end of October - WHO pandemic phase 6 declared - Start of Clinical 2009 onwards on 11 June Trials - Receipt of PhVg data - Receipt of clinical data in adults and in children 10 What has been done by the EMEA to achieve approval of pandemic vaccines? z Regular strategy meetings z EMEA meetings with companies z Participation in Health Security Committee meetings (DG SANCO) z Participation in ongoing Ad hoc task-force meetings on vaccine development and vaccination strategy (SANCO-ENTR- EMEA-ECDC) z International discussions – teleconferences with WHO and interactions with FDA/Health Canada/Japan /TGA 11 Timelines to availability of data for mock-up vaccines 24 Sept 2009 CHMP opinion 1 Oct 2009 strain change 29 Sept 2009 CHMP opinion 6 Oct 2009 MA- H5N1 granted: variation H1N1 EC decision Strain change Focetria 2-05-07 received for received for variation H1N1 EC decision Pandemrix 20-05-08 Pandemrix and Pandemrix and received for received for Celvapan 4-03-09 Focetria Focetria Celvapan Celvapan July –Sept 2009 Mid October 2009 Oct/Dec 2009 Nov 09- Feb Quality data packages Clinical immunogenicity First/ interim 10 relating to A(H1N1)v data received adult clinical data Time to with the availability of vaccines submitted - PI have been updated A(H1N1)v first/ interim for Pandemrix and vaccines paediatric data Focetria 12 Product Information - Vaccines z Clinical Indication: Prophylaxis of influenza in an officially declared pandemic situation. z Data for mock up MAs are available in adults (18-60 years) and the elderly (>60), and, in some cases, also in children. z The Product Information does not preclude the use of these vaccines in any age group or special population group. There is a clear statement that these vaccines should be used in accordance with official guidance. Benefit-risk were evaluated by CHMP for each age group. z Thus, they allow national authorities to use these vaccines in population groups for which there are no data, if they perceive that there is a need to do so. For example: » Young children » Very elderly (> 80 years ) » Pregnant Women 13 Post Authorisation - Product Risk Management Plan z Stringent post-marketing surveillance commitments are in place for all mock ups in their Risk Management Plan as follows: » For each vaccine, the company will perform a post-marketing study on 9,000 patients across all age groups, recruited at the start of the vaccination campaign. » Each company will provide every month a report (simplified Periodic Safety Update Report [PSUR]) on all adverse reports notified by patients and HCPs. » Adverse events as well as adverse events of special interest (e.g. neurological disorders) that have been identified based on experience with similar vaccines will be specifically monitored for the pandemic vaccines together with other adverse events. » Special population groups, such as pregnant women, children and immuno-compromised subjects will be specifically monitored in the post-marketing study, using existing or newly established registries and networks of healthcare professionals. 14 Post Authorisation -Product Risk Management Plan z Extensive amounts of safety and efficacy data are / will be received in a very short space of time after the initial authorisation of the pandemic strain change variation. » Therefore, patients will need to have access to the very latest information updates and HCPs will receive information to reinforce traceability of the products and stimulate adverse event reporting. z The use in larger vaccination campaigns will facilitate detection of rare vaccine associated adverse events z The effectiveness of use in the field is monitored in accordance with protocols developed by the ECDC 15 Clinical data review z Clinical immunogenicity data for Celvapan, Focetria and Pandemrix was received in October z Following review of the data, the CHMP maintained its recommendations adopted in September: the 3 vaccines should preferably be used as 2 doses, at least 3 weeks apart z However, for Pandemrix and Focetria, the limited data currently available indicate that 1 dose may be sufficient in adults. z A 1 dose schedule may be used in healthy adults and consideration can be given to using the same schedule in children and adolescents (> 10 years old) z This recommendation, which already applied to Pandemrix, can now also be applied to Focetria. The data for Celvapan are still insufficient for the CHMP to modify its previous position. 16 Clinical data review z For Pandemrix: » The additional data with the H1N1 vaccine confirmed the recommendation made in September. » The vaccine should preferably be used as a 2-dose schedule, but 1 dose may be sufficient in adults 18- 60 and consideration can be given to using the same 1 dose schedule in children and adolescents (> 10 years old). » The immunogenicity results show that 1 dose of Pandemrix brought about an appropriate level of protection z For Focetria: » The data are sufficient to conclude that the vaccine should preferably be used as a 2-dose schedule, but 1 dose may be sufficient in adults 18-60. This is based on immunogenicity results in healthy adults 3 weeks after vaccination that satisfied all of the CHMP’s criteria » Consideration can be given to using the same 1 dose schedule in children and adolescents (> 9 years old). z For Celvapan: » While the CHMP awaits further data, the dosage schedule remains as 2 doses, with a 3 week interval, in all populations. 17 Overview of presentation z Preparedness activities (2003-2009) z Current activities (April to October 2009) z CurrentCurrent situationsituation -- VaccinesVaccines 18 Concluding Remarks - 1 z 3 vaccines for H1N1 pandemic influenza have received an EC Decision: » Focetria (Novartis) on 29-10-09 » Pandemrix (GSK Biologicals) on 29-10-09 » Celvapan (Baxter) on 06-10-09 z EMEA has worked closely with companies and other stakeholders

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    32 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us